HMGCR and colon carcinoma in situ: For the subgroups in which replication analysis was not feasible (Table S4), we observed that HMGCR‐mediated LDL was negatively associated with lower third EC (OR = 0.16, 95% CI: 0.05–0.52, p < 0.01), colon in situ carcinoma (OR = 0.20, 95% CI: 0.05–0.82, p = 0.03), and anal canal cancer (OR = 0.16, 95% CI: 0.03–0.83, p = 0.03).